Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00510133 · ClinicalTrials.gov registry record · Phase 2

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

A Phase 2 study of Acute Myelogenous Leukemia, sponsored by Asterias Biotherapeutics.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target
6
Study locations

NCT00510133 is a Phase 2 study of Acute Myelogenous Leukemia that has completed, run by Asterias Biotherapeutics. The registered enrollment target is 21 participants, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00510133, a Phase 2 study of Acute Myelogenous Leukemia, has completed, sponsored by Asterias Biotherapeutics.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target
6
Study locations

Study Summary

This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

Conditions Studied

Acute Myelogenous Leukemia

Interventions

  • BIOLOGICAL GRNVAC1

Study Locations (6)

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • Loyola University Medical Center - Maywood

Missouri

  • Washington University School of Medicine, Siteman Cancer Center - St Louis

Nebraska

  • University of Nebraska Medical Center - Omaha

Ohio

  • Ohio State University - Columbus

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2007-07
Est. Completion 2014-08
Phase Phase 2

Sponsor

Asterias Biotherapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00510133

The ClinicalTrials.gov registry entry for NCT00510133 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (85% lower). The listed sponsor is Asterias Biotherapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which GRNVAC1 is the first listed.

NCT00510133 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT00510133 about?

NCT00510133 is a clinical study titled "A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)". This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

What is the current status of trial NCT00510133?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-07. Estimated completion is 2014-08.

What conditions does trial NCT00510133 study?

This clinical trial studies the following conditions: Acute Myelogenous Leukemia.

What interventions are being tested in trial NCT00510133?

The interventions under investigation include: GRNVAC1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00510133?

This trial is sponsored by Asterias Biotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00510133 being conducted?

This trial has 6 study locations across Georgia, Illinois, Missouri, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myelogenous Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myelogenous Leukemia

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.